Oh Geez, it is totally about biomarker results & also the number of patients needed for statistical analysis at each Interim analysis (refer to trial design) for Endpoints. The story keeps changing, & make sure you factor in Rare disease & Orphan status into those numbers. Completely different for most regulatory approvals (dual PH3 trials & thousands of participants).
Enjoy your time travelling & take care. If you have the statistical analysis formula from a double blinded & quadruple masked trial from the ACTION3 trial, GL with that. There are others to compare to.
- Forums
- ASX - By Stock
- DXB
- Ann: Application for quotation of securities - DXB
Ann: Application for quotation of securities - DXB, page-113
-
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
56.0¢ |
Change
0.035(6.67%) |
Mkt cap ! $308.1M |
Open | High | Low | Value | Volume |
51.5¢ | 57.3¢ | 50.5¢ | $2.179M | 3.991M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 30558 | 56.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
56.5¢ | 10000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 30558 | 0.560 |
3 | 25521 | 0.555 |
7 | 539331 | 0.550 |
3 | 15269 | 0.545 |
2 | 7430 | 0.540 |
Price($) | Vol. | No. |
---|---|---|
0.565 | 10000 | 1 |
0.570 | 73781 | 4 |
0.575 | 47975 | 3 |
0.580 | 122045 | 5 |
0.585 | 107509 | 5 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |